SlideShare a Scribd company logo
1 of 20
Download to read offline
Good practice
in international
medicine
donations
A project by: With the support of:
2
© Copyright by: Farmamundi
Edited by:
Farmamundi Catalunya
C/Erasme de Janer 8
08001 - Barcelona
Telf: 93 244 44 55
www.farmamundi.org
With the support of:
Design by:
La Guspira
Publication date:
January 2019
INDEX
INTRODUCTION.......................................................................4
GENERAL CONSIDERATIONS...............................................5
SELECTION OF MEDICINES...................................................6
PRESENTATION, PACKAGING AND LABELLING............8
TRANSPORT..............................................................................9
INFORMATION AND MANAGEMENT............................11
MANAGEMENT OF USED MEDICINES............................13
KEY CONCEPTS.....................................................................13
ACRONYMS............................................................................15
BIBLIOGRAPHY.....................................................................15
NOTES.......................................................................................17
4
INTRODUCTION
Medicine donations occur in very different circumstances; as a response to
emergency situations, to humanitarian crises, or in long-term development aid
projects. In emergency situations, part of the solidary response to the affected
population is in the form of medicine donations. Although these contributions
are almost always unquestionable and made in good faith, the rule “something
is always better than nothing” is not correct. Even though; medicines are
fundamental in humanitarian interventions they may have future negative
consequences for the environment and for the health of the people of the
receiving country. It has been found through the years, that medicines donated
spontaneously do not always correspond to the needs of the emergency, the
morbidity or the level of care of the recipient country. In these cases, not only
candonationshavenegativeeffectsforthereceivingcommunitiesbutmayeven
go unnoticed by health personnel or patients in the area, and not in line with the
local pharmaceutical policies or the treatment guidelines of the country.
It is also important to highlight the incorrect statement that “in situations of
serious emergencies medicines with a short expiration date can be donated because
they will be used quickly”, because it is precisely in these situations, when the
systems for receiving, storing and distributing medicines, as it happens with
other supplies, can be disrupted and overloaded, causing accumulations
before its final distribution. These delays are especially serious when it comes
to medicines, when their expiry date comes into play. Local and international
health organizations, as well as public and private entities, have repeatedly
denounced over the years, the massive arrival of medicines not usable in the
countries affected by crisis situations, and the problems that derive from their
incorrect storage, irrational use and eventual destruction.
In 1996, the World Health Organization (WHO) [1] published for the first
time a document of guidelines for medicine donations, reviewed and ratified
in 1999 by this agency, as well as by social and international organizations,
until the last update in 2010 [2]. These recommendations have served the
international community as the basis for international legislation, such as the
Guidelines on Good Distribution Practice of Medicinal Products for human
use of the European Economic Community (EEC) [3] and national laws. In the
case of the Spanish State, it is the Spanish Agency for Medicines and Health
Products (AEMPS) [4] that regulates international medicine donations. These
instructions for exports of medicines for humanitarian aid [5], are aimed at
maintaining the quality standards of the medicines regardless of who the
recipients are, and they forbid the donation of medicines that have already
been used or that have left the pharmaceutical circuit.
5
GENERAL
CONSIDERATIONS
The aim of the WHO recommendations and of Spanish legislation on
internationaldonationsofmedicines,istoensurethequalityofmedicinestoall
people, whatever their circumstances. According to those recommendations
and legislation, donated medicines must comply with all the international
standards of quality, and not have abandoned the pharmaceutical circuit that
ensures their traceability.
International donations of medicines must always be endorsed by
pharmaceutical staff who assume the responsibility for their quality and who
certify their validity for shipment.
It is also necessary that the recipient is informed, in good time, of the arrival
date and the expiry dates of the medicines that, according to Spanish
legislation, must be longer than 15 months. Only in very special circumstances
and with the written acceptance of the recipient, medicines with lower
expiry dates can be sent as a donation. This is so, because in many receiving
countries, there may be logistical problems such as poor transport systems,
storage problems or long distances between the ports of arrival and the final
destination, delaying the delivery of the medicines. Similarly, the different
storage levels from origin to destination (port or airport, central warehouse,
provincial warehouse, district hospital, health centre) can lead to long delivery
times of up to six to nine months, reducing the expiry dates of the medicines,
before being delivered. Therefore, the recipients of the donation must be kept
informed of the all stages of this process. They must also know the quantities
and expiry dates of the medicines, because an excessive delay, in any of these
phases, can imply quality deterioration of the medicines, affecting the stocks
of the health centres, and generating harmful waste for the environment.
The unusable medicines that arrive at destination should be eliminated in an
appropriate manner, as they can become emerging organic pollutants, turning
into an added problem for the recipient country, if it does not have adequate
waste management processes.
Whenever possible, donated medicines should be sent in big formats and
appropriately labelled for final administration by the health professionals.
Finally, it must be stressed that international donations of medicines
cannot be managed by or sent to private individuals, but directly by non-
6
governmental organizations (NGOs) or humanitarian aid foundations,
pharmaceutical laboratories, distributors of medicines, hospitals, health
centres or governments, and addressed to governments or entities accredited
by the Ministry of Health of the country of destination.
SELECTION OF
MEDICINES
The medicines registered in Spain being selected for donation must always
comply with all the international quality guarantees. In the case of medicines
not registered in Spain, they must be:
•	 registered in a European Union country (EU), or
•	 registered outside the European Union and have the corresponding
Certificate of Good Manufacturing Standards (GMP) issued by
the European Union to guarantee their quality. In these cases, and
exceptionally, the export can be authorized as a humanitarian donation
and must be accompanied by a declaration signed by the recipient
health authorities that details:
a) identification of the medicines: name of the medicine, presentation
and name of the manufacturing laboratory.
b) express acceptance of the shipment, stating that they are aware that
the donated medicine is not registered in the European Union.
Donated medicines must have:
•	 thesameguaranteesofquality,safetyandefficacyasthosebeingused
in the country of origin and therefore remain within the pharmaceutical
circuit, that is, in the legal chain of custody, until their final delivery.
	
•	 a minimum expiry time of fifteen months upon arrival in the receiving
country, with the exception of direct donations to certain health
facilities. In these cases, a declaration from the recipient health
personnel is necessary, acknowledging the expiry dates, storage
conditions, and the amount being sent to prepare for the appropriate
administration, before the expiry date.
7
•	 the prior authorization of the recipient, who has had to specify its
needs. The legislation authorizes the recipient to refuse unsolicited
donations, those that arrive without prior notice, or are not necessary,
in order to guarantee the pharmaceutical policies and essential drug
programmes of the recipient country, and maximize the positive impact
of the donation, preventing the arrival of unnecessary and/or unknown
medicines.
•	 the presentation, dose and formulation as similar as possible to those
of the recipient country to facilitate the work of its health personnel
who are used to administering certain formulas and following dose
guidelines without modification, so as not to affect the quality of their
work.
Neither medicines that come from patients’ returns, nor those provided
as free samples to health personnel, can be donated, as it is not possible to
guarantee their quality.
Restrictions and exceptions
* Psychotropic drugs, blood products, narcotics, heat-labile medicines or
those with special storage and/or transportation conditions are given special
consideration and their donation must be duly justified. These medicines
8
require a special export authorization, which is processed by the Narcotics
and Psychotropic Area of the AEMPS, that will accompany the export
authorization of medicines for humanitarian donations.
* Vaccines, which apart from having special storage and/or transport
conditions, are usually administered under national vaccination plans and
international agreements, and consequently, not being part of smaller scale
donations, between entities
PRESENTATION,
PACKAGING AND
LABELLING
To facilitate the administration, storage and distribution of international
medicine donations, especially in emergency situations, clear identification
of the boxes and their contents is very important, otherwise, the shipping
operations can become very slow and laborious, delaying the delivery of
medicines to the recipient.
•	 The packaging must allow for clear identification of the medicines,
thatis, includetheInternationalCommonDenomination(ICD)orgeneric
name, dosage, pharmaceutical form, batch number, manufacturer and
9
expiry date. Receiving medicines with different or unknown names,
can be a source of confusion for the heath personnel. In the case of
injectables, the route of administration must also be clearly indicated. It
is also recommended that the language of the labelling is intelligible for
the health professionals of the receiving country.
•	 It is advisable to adapt the packaging (commercial or hospital) to the
conditions of the recipient, taking also into account issues like the price
of different formats or means of transport, to maximizing the resources
assigned to the donation.
TRANSPORT
At no time during the transport of the medicines, that is, from the warehouse
of origin to their arrival in the receiving country, can the boxes that contain
the medicines be opened, to add or remove any items. Until that moment, the
number of boxes, weights and contents must correspond to the associated
export documentation: commercial invoice, packing list and donation letter
10
stating that the donated goods will have, at destination, a non-commercial and
assistance use.
Medicines must be packed in separate boxes to the rest of the products, not
mixing them with other types of supplies. To facilitate the handling of the
shipment, without the need for special equipment, the boxes should not weigh
more than 23kg.
Costs
Transportation costs (local and international), deposit and custody, customs
clearance, storage or appropriate handling are borne by the donor entity, unless
otherwise agreed in advance with the recipient, so as not to force it to allocate
funds and efforts for the payment of customs and transport costs.
11
INFORMATION AND
MANAGEMENT
The export of medicines, as an international donation, together with the
compulsory authorization of the AEMPS must accompany, for tax purposes,
the necessary documentation:
1.	 commercial invoice based on the wholesale price of their generic
equivalent in the local market. If this information is not available, one
must consider the wholesale price in the world market of their generic
equivalent. The declared value may also include management expenses.
2.	 packing list.
3.	 letter of donation issued by the donor entity indicating the destination,
the value of the medicines, and a statement indicating that the donated
medicines will be used for health purposes, and not commercial use.
4.	 information of the customs office of departure (port or airport).
Because the documentation for the export includes the list of contents of each
box, the authorization to the AEMPS must be requested, once the order is fully
assembled.
The application is free of charge and can be submitted:
•	 In the virtual office of the AEMPS, going to the LABOFAR application:
https://labofar.aemps.es/labofar/inicial.do
•	 In paper format
The export authorization of medicines:
•	 is unique and exclusive for each donation, but not necessary for medical
equipment and cosmetic products.
•	 is valid for three months
An authorized medicine donation may never have a commercial purpose.
12
There are two types of donour entities:
A) with European Tax Identification Number:
i. Shipments delivered in Spain; known informally as “suitcase shipments”.
In these cases, the donor entity acts as an exporter of medicines and is
ultimately responsible for the shipment. It is this entity that applies to
the AEMPS for the export authorization of medicines and is responsible
for the rest of the customs documentation. The responsibility of the
medicines’ distributor ends with the delivery at the address given by the
donor. Nonetheless, the distributor must provide the documentation and
the advice, if necessary, for applying for the export authorization.
ii. Shipments delivered to the country of destination. The distributor
acts as the exporter and is responsible for the processing of the export
authorisation and related documentation.
B) ) with a non-European Tax Identification Number:
Shipments are delivered in countries that are not members of the EU
and are considered as commercial exports, thus not requiring a donation
letter. In these cases, it is the distributor who is responsible for the export
and custom procedures with the pertinent administrations.
To apply for the export authorization of medicines, you must submit:
1)	 List of medication packaging indicating:
•	 Name of the medicine (ICD).
•	 Registrationnumber,whenthemedicineisregisteredformarketing
in an EU Member State or a Certificate of Good Manufacturing
Standards, in other circumstances.
•	 Holder of the marketing authorization.
•	 Presentation: pharmaceutical form, dosage and format and lot
number.
•	 Expiry date.
•	 Number of boxes of each medicine.
•	 Mention: These medicines are a free of charge donation of
humanitarian character by (name of the entity).
2)	 Certificate signed by the responsible pharmacist who guarantees
the shipment according to the criteria established for the international
donation of medicines.
13
MANAGEMENT OF
USED MEDICINES
Left over medicines from our homes, as well as the empty packaging or with
remnants of medicines, should be taken to the SIGRE Points [6] that are found
in pharmacies, with their original boxes to facilitate their identification and
their subsequent environmental treatment or other. Needles, thermometers,
gauze and material for cures, chemicals, x-rays or batteries cannot be put into
the SIGRE Points. As an exception, only when it is not possible to separate the
needle, pre-filled syringes, insulin pens or other pens can they be taken to the
SIGRE. In this case, they should always be deposited with the needle capped
with their protective cap or similar. For safety and public health reasons,
SIGRE Points are exclusively in pharmacies, so that the residues of medicines
are always in the custody of pharmaceutical professionals.
Finally, according to the Packaging and Packaging Waste Law (Law 1/1997 of
April 24) [7] is the pharmaceutical productive sector who is obliged to assume
the management of the waste of medicines that have to be destroyed in a
controlled manner, and the recycling of the cardboard, glass, paper, etc., so as
to not contaminate the environment.
KEY CONCEPTS
Bioequivalence
Bioequivalence is the property wherein two drugs with identical active
ingredients or two different dosage forms of the same drug possess similar
bioavailability and produce the same effect at the site of physiological activity.
Emerging contaminant
Emerging contaminant is that previously unknown or not recognized
substance, whose presence is not necessarily new, but what is new is the
concern over its possible effects in the environment. The detection of these
pollutants has only recently been possible thanks to the development of new
and more sensitive analytical technologies.
14
Neglected diseases
Neglected diseases are those that persist when there is poverty and are
concentrated almost exclusively in the poor and impoverished countries of
the world. These populations, living in remote rural areas, marginal suburban
neighbourhoods or conflict zones, tend to be the most affected by these
diseases,towhichlittleresearchanddevelopmentisdestinedandarerelegated
from public health priorities because of their lack of political influence. Also,
the lack of reliable statistics hinders initiatives to highlight them.
Essential medicines
Essential medicines are those that cover the priority health care needs of the
population. Their selection is based on the prevalence of diseases and their
safety,efficacyandcomparativecost-effectiveness.Nationaldruglistsindicate
the essential medicines that must always be available, in sufficient quantities,
in the appropriate pharmaceutical forms, with a guaranteed quality, and at a
price that is affordable for people and for the community.
TheWorldHealthOrganizationpublishedthefirstlistofessentialmedicinesin
1977, that is reviewed and updated every two years to adapt it to the changing
health challenges in the world, serving as a model for Member States. In March
2017, the twentieth revision of the Essential Medicines List was published
and the sixth revision for children under 12 years of age [8]. The twentieth
list includes 433 medicines to treat priority diseases such as malaria, HIV/
AIDS, tuberculosis, reproductive health disorders and the increasingly chronic
diseases, including cancer and diabetes.
15
Generic drugs
Generic medicines are those that have the same qualitative and quantitative
composition in active principles and the same pharmaceutical form as the
original medicines and have demonstrated bioequivalence with the original
medicines.
Morbidity
Morbidity is the number of people considered ill or victims of illness in a given
space and time. Morbidity is an important statistical data to understand the
evolution or regression of any disease, the reasons for its emergence and
possible solutions.
16
ACRONYMS
AEMPS
AIDS
EEC
EU
GMP
HIV
ICD
NGO
WHO
- Agencia Española del Medicamento y Productos Sanitarios
- Acquired Immunodeficiency Syndrome
- European Economic Community
– European Union
– Good Manufacturing Practices
- Human Immunodeficiency Virus
- International Common Denomination
- Non-Governmental Organization
- World Health Organization
17
BIBLIOGRAPHY
[1] Web page of the World Health Organisation (WHO).
http://www.who.int/es/
[2] Guidelines for Medical Donations (WHO).
http://apps.who.int/iris/bitstream/10665/44647/1/9789241501989_eng.pdf
[3] ] Guidelines of 5 November 2013on Good Distribution Practice of medici-
nal products for human use.
https://www.aemps.gob.es/medicamentosUsoHumano/donaciones/docs/ins-
trucciones-donacion-med.pdf
[4] Web page of the Spanish Agency for Medicines and Health Products.
(AEMPS).
https://www.aemps.gob.es/
[5] Instructions for the export of medicnes for humanitarian donations.
(AEMPS). Ministry of Health, Consumer Affairs and Social Welfare.
https://www.aemps.gob.es/medicamentosUsoHumano/donaciones/docs/ins-
trucciones-donacion-med.pdf
[6] Web page of SIGRE (Sistema Integral de Gestión de Residuos y Envases).
https://www.boe.es/buscar/doc.php?id=BOE-A-1997-8875
[7] Legislation on Packaging and Packaging Waste (Law 1/1997 April 24). BOE.
http://www.sigre.es/
[8] WHO Model List of Essential Medicines.
https://www.who.int/medicines/publications/essentialmedicines/20th_
EML2017.pdf?ua=1
WHO Model List of Essential Medicines for Children
https://apps.who.int/iris/bitstream/handle/10665/273825/EMLc-6-eng.
pdf?ua=1
18
NOTES
19
20
A project by:
With the support of:

More Related Content

What's hot

Nomenclature of steroids
Nomenclature of steroidsNomenclature of steroids
Nomenclature of steroidsShrutiMistry5
 
Oxazole ring-containing-drugs (1)
Oxazole ring-containing-drugs (1)Oxazole ring-containing-drugs (1)
Oxazole ring-containing-drugs (1)Tousif Azmain
 
Pharmaceutical excipients
Pharmaceutical excipientsPharmaceutical excipients
Pharmaceutical excipientsHossen M. Faruk
 
3rd unit anti-hyperlipidemic agents ppt
3rd  unit  anti-hyperlipidemic  agents ppt3rd  unit  anti-hyperlipidemic  agents ppt
3rd unit anti-hyperlipidemic agents pptNikithaGopalpet
 
Pharmaceutical Jurisprudence
Pharmaceutical JurisprudencePharmaceutical Jurisprudence
Pharmaceutical JurisprudenceBikashAdhikari26
 
MCQs on Drug de-addiction and Drugs of Abuse
MCQs on Drug de-addiction and Drugs of AbuseMCQs on Drug de-addiction and Drugs of Abuse
MCQs on Drug de-addiction and Drugs of AbuseShivankan Kakkar
 
Narcotic drugs & psychotropic substances act,1985 with rules 1985
Narcotic drugs & psychotropic substances act,1985 with rules 1985Narcotic drugs & psychotropic substances act,1985 with rules 1985
Narcotic drugs & psychotropic substances act,1985 with rules 1985Ravikumar Patil
 
Antineoplastic agents/Anticancer Drugs
Antineoplastic agents/Anticancer DrugsAntineoplastic agents/Anticancer Drugs
Antineoplastic agents/Anticancer DrugsAnjali Bhardwaj
 
tetracyclins.pdf
tetracyclins.pdftetracyclins.pdf
tetracyclins.pdfAishaAltaf6
 
Introduction to Pharmaceutical Jurisprudence
Introduction to Pharmaceutical JurisprudenceIntroduction to Pharmaceutical Jurisprudence
Introduction to Pharmaceutical JurisprudencePranay Sethiya
 
Medicinal diuretics by Waris Nawaz
Medicinal diuretics by Waris NawazMedicinal diuretics by Waris Nawaz
Medicinal diuretics by Waris Nawazwaris88
 
pyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdfpyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdfChintuCH1
 
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).ppt
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).pptCOMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).ppt
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).pptSumit Tiwari
 
Pharmacy act, 1948
Pharmacy act, 1948Pharmacy act, 1948
Pharmacy act, 1948sheelathorat
 

What's hot (20)

Anti malarial drugs
Anti malarial drugsAnti malarial drugs
Anti malarial drugs
 
Nomenclature of steroids
Nomenclature of steroidsNomenclature of steroids
Nomenclature of steroids
 
Oxazole ring-containing-drugs (1)
Oxazole ring-containing-drugs (1)Oxazole ring-containing-drugs (1)
Oxazole ring-containing-drugs (1)
 
Pharmaceutical excipients
Pharmaceutical excipientsPharmaceutical excipients
Pharmaceutical excipients
 
3rd unit anti-hyperlipidemic agents ppt
3rd  unit  anti-hyperlipidemic  agents ppt3rd  unit  anti-hyperlipidemic  agents ppt
3rd unit anti-hyperlipidemic agents ppt
 
Pharmaceutical Jurisprudence
Pharmaceutical JurisprudencePharmaceutical Jurisprudence
Pharmaceutical Jurisprudence
 
MCQs on Drug de-addiction and Drugs of Abuse
MCQs on Drug de-addiction and Drugs of AbuseMCQs on Drug de-addiction and Drugs of Abuse
MCQs on Drug de-addiction and Drugs of Abuse
 
Narcotic drugs & psychotropic substances act,1985 with rules 1985
Narcotic drugs & psychotropic substances act,1985 with rules 1985Narcotic drugs & psychotropic substances act,1985 with rules 1985
Narcotic drugs & psychotropic substances act,1985 with rules 1985
 
Haematinics
HaematinicsHaematinics
Haematinics
 
Antineoplastic agents/Anticancer Drugs
Antineoplastic agents/Anticancer DrugsAntineoplastic agents/Anticancer Drugs
Antineoplastic agents/Anticancer Drugs
 
tetracyclins.pdf
tetracyclins.pdftetracyclins.pdf
tetracyclins.pdf
 
Introduction to Pharmaceutical Jurisprudence
Introduction to Pharmaceutical JurisprudenceIntroduction to Pharmaceutical Jurisprudence
Introduction to Pharmaceutical Jurisprudence
 
PHARMACOPOEIA.pptx
PHARMACOPOEIA.pptxPHARMACOPOEIA.pptx
PHARMACOPOEIA.pptx
 
Medicinal diuretics by Waris Nawaz
Medicinal diuretics by Waris NawazMedicinal diuretics by Waris Nawaz
Medicinal diuretics by Waris Nawaz
 
D _c_act
D  _c_actD  _c_act
D _c_act
 
pyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdfpyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdf
 
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).ppt
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).pptCOMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).ppt
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).ppt
 
Pharmacy act, 1948
Pharmacy act, 1948Pharmacy act, 1948
Pharmacy act, 1948
 
Protectives
ProtectivesProtectives
Protectives
 
Steroids
SteroidsSteroids
Steroids
 

Similar to Good practice in international medicine donations

Good practices for International Medicine Donations
Good practices for International Medicine DonationsGood practices for International Medicine Donations
Good practices for International Medicine Donationsfarmamundicatalunya
 
Role of Pharmacist in COVID19.pptx
Role of Pharmacist in COVID19.pptxRole of Pharmacist in COVID19.pptx
Role of Pharmacist in COVID19.pptxSachinBhosale73
 
PAGE 1State Pharmacy BrazilnamePracticum in Health Administ.docx
PAGE  1State Pharmacy BrazilnamePracticum in Health Administ.docxPAGE  1State Pharmacy BrazilnamePracticum in Health Administ.docx
PAGE 1State Pharmacy BrazilnamePracticum in Health Administ.docxalfred4lewis58146
 
1)spontanious reporting schemes for biodrug adverse reactions
1)spontanious reporting schemes for biodrug adverse reactions1)spontanious reporting schemes for biodrug adverse reactions
1)spontanious reporting schemes for biodrug adverse reactionsNeha Suresh
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacyKARTHIKA K.J
 
Introduction to community pharmacy.pdf
Introduction to community pharmacy.pdfIntroduction to community pharmacy.pdf
Introduction to community pharmacy.pdfMohamedAliMohamedEli
 
RDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfRDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfrishi2789
 
عرض تقديمي دعائي عصري أبيض وأرجواني.pptx
عرض تقديمي دعائي عصري أبيض وأرجواني.pptxعرض تقديمي دعائي عصري أبيض وأرجواني.pptx
عرض تقديمي دعائي عصري أبيض وأرجواني.pptxOmarAlqadi5
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacyIti Chauhan
 
Pharmacy Practice Presentation1.pptx
Pharmacy Practice Presentation1.pptxPharmacy Practice Presentation1.pptx
Pharmacy Practice Presentation1.pptxmZOn2
 
Community Pharmacy Ravinandan A P 7th Sem.pptx
Community Pharmacy  Ravinandan A P 7th Sem.pptxCommunity Pharmacy  Ravinandan A P 7th Sem.pptx
Community Pharmacy Ravinandan A P 7th Sem.pptxRavinandan A P
 
Market Access Database Spain 2013
Market Access Database Spain 2013Market Access Database Spain 2013
Market Access Database Spain 2013Josep Darba
 
Guidelines for Drug Donation to Nepal (DDA)
Guidelines for Drug Donation to Nepal (DDA)Guidelines for Drug Donation to Nepal (DDA)
Guidelines for Drug Donation to Nepal (DDA)Nabin Bist
 
Basics of Drug Information.pptx
Basics of Drug Information.pptxBasics of Drug Information.pptx
Basics of Drug Information.pptxHhggg8
 
communitypharmacy ppt.pdf
communitypharmacy ppt.pdfcommunitypharmacy ppt.pdf
communitypharmacy ppt.pdfShikhaSachde
 

Similar to Good practice in international medicine donations (20)

Good practices for International Medicine Donations
Good practices for International Medicine DonationsGood practices for International Medicine Donations
Good practices for International Medicine Donations
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
Role of Pharmacist in COVID19.pptx
Role of Pharmacist in COVID19.pptxRole of Pharmacist in COVID19.pptx
Role of Pharmacist in COVID19.pptx
 
PAGE 1State Pharmacy BrazilnamePracticum in Health Administ.docx
PAGE  1State Pharmacy BrazilnamePracticum in Health Administ.docxPAGE  1State Pharmacy BrazilnamePracticum in Health Administ.docx
PAGE 1State Pharmacy BrazilnamePracticum in Health Administ.docx
 
1)spontanious reporting schemes for biodrug adverse reactions
1)spontanious reporting schemes for biodrug adverse reactions1)spontanious reporting schemes for biodrug adverse reactions
1)spontanious reporting schemes for biodrug adverse reactions
 
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
clinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptxclinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptx
 
Introduction to community pharmacy.pdf
Introduction to community pharmacy.pdfIntroduction to community pharmacy.pdf
Introduction to community pharmacy.pdf
 
RDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfRDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdf
 
عرض تقديمي دعائي عصري أبيض وأرجواني.pptx
عرض تقديمي دعائي عصري أبيض وأرجواني.pptxعرض تقديمي دعائي عصري أبيض وأرجواني.pptx
عرض تقديمي دعائي عصري أبيض وأرجواني.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
Essential medicine
Essential medicineEssential medicine
Essential medicine
 
Pharmacy Practice Presentation1.pptx
Pharmacy Practice Presentation1.pptxPharmacy Practice Presentation1.pptx
Pharmacy Practice Presentation1.pptx
 
Community Pharmacy Ravinandan A P 7th Sem.pptx
Community Pharmacy  Ravinandan A P 7th Sem.pptxCommunity Pharmacy  Ravinandan A P 7th Sem.pptx
Community Pharmacy Ravinandan A P 7th Sem.pptx
 
Market Access Database Spain 2013
Market Access Database Spain 2013Market Access Database Spain 2013
Market Access Database Spain 2013
 
Guidelines for Drug Donation to Nepal (DDA)
Guidelines for Drug Donation to Nepal (DDA)Guidelines for Drug Donation to Nepal (DDA)
Guidelines for Drug Donation to Nepal (DDA)
 
Basics of Drug Information.pptx
Basics of Drug Information.pptxBasics of Drug Information.pptx
Basics of Drug Information.pptx
 
communitypharmacy ppt.pdf
communitypharmacy ppt.pdfcommunitypharmacy ppt.pdf
communitypharmacy ppt.pdf
 

More from farmamundicatalunya

Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...
Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...
Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...farmamundicatalunya
 
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...farmamundicatalunya
 
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...farmamundicatalunya
 
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...farmamundicatalunya
 
Estar embarazada y parir en barcelona
Estar embarazada y parir en barcelonaEstar embarazada y parir en barcelona
Estar embarazada y parir en barcelonafarmamundicatalunya
 
Estar embarazada i Parir en Barcelona
Estar embarazada i Parir en BarcelonaEstar embarazada i Parir en Barcelona
Estar embarazada i Parir en Barcelonafarmamundicatalunya
 
Dons internationaux de médicaments. Comment les faire de manière appropriée
Dons internationaux de médicaments. Comment les faire de manière appropriéeDons internationaux de médicaments. Comment les faire de manière appropriée
Dons internationaux de médicaments. Comment les faire de manière appropriéefarmamundicatalunya
 
Bonnes pratiques pour le don international de médicaments
Bonnes pratiques pour le don international de médicamentsBonnes pratiques pour le don international de médicaments
Bonnes pratiques pour le don international de médicamentsfarmamundicatalunya
 
أفضل الممارسات للتبرعات الدولية للأدوية
أفضل الممارسات للتبرعات الدولية للأدويةأفضل الممارسات للتبرعات الدولية للأدوية
أفضل الممارسات للتبرعات الدولية للأدويةfarmamundicatalunya
 
Donaciones apropiadas de medicamentos
Donaciones apropiadas de medicamentosDonaciones apropiadas de medicamentos
Donaciones apropiadas de medicamentosfarmamundicatalunya
 
Buenas practicas para la donación internacional de medicamentos
Buenas practicas para la donación internacional de medicamentosBuenas practicas para la donación internacional de medicamentos
Buenas practicas para la donación internacional de medicamentosfarmamundicatalunya
 
Bones pràctiques per a la donació internacional de medicaments
Bones pràctiques per a la donació internacional de medicaments Bones pràctiques per a la donació internacional de medicaments
Bones pràctiques per a la donació internacional de medicaments farmamundicatalunya
 
Donacions Internacionals de Medicaments. Com fer-les apropiadament
Donacions Internacionals de Medicaments. Com fer-les apropiadamentDonacions Internacionals de Medicaments. Com fer-les apropiadament
Donacions Internacionals de Medicaments. Com fer-les apropiadamentfarmamundicatalunya
 

More from farmamundicatalunya (15)

Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...
Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...
Informe | Atendre l'embaràs i el part a Barcelona. Imatges i veus de professi...
 
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...
Recomanacions | Atendre l'embaràs i el part a Barcelona. Imatges i veus de pr...
 
Gènere i Salut
Gènere i SalutGènere i Salut
Gènere i Salut
 
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...
Dossier professorat projecte Educació i Acció Transformadora per a l’equitat ...
 
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...
Dossier alumnat projecte Educació i Acció Transformadora per a l’equitat de g...
 
Estar embarazada y parir en barcelona
Estar embarazada y parir en barcelonaEstar embarazada y parir en barcelona
Estar embarazada y parir en barcelona
 
Estar embarazada i Parir en Barcelona
Estar embarazada i Parir en BarcelonaEstar embarazada i Parir en Barcelona
Estar embarazada i Parir en Barcelona
 
Gènere i salut
Gènere i salutGènere i salut
Gènere i salut
 
Dons internationaux de médicaments. Comment les faire de manière appropriée
Dons internationaux de médicaments. Comment les faire de manière appropriéeDons internationaux de médicaments. Comment les faire de manière appropriée
Dons internationaux de médicaments. Comment les faire de manière appropriée
 
Bonnes pratiques pour le don international de médicaments
Bonnes pratiques pour le don international de médicamentsBonnes pratiques pour le don international de médicaments
Bonnes pratiques pour le don international de médicaments
 
أفضل الممارسات للتبرعات الدولية للأدوية
أفضل الممارسات للتبرعات الدولية للأدويةأفضل الممارسات للتبرعات الدولية للأدوية
أفضل الممارسات للتبرعات الدولية للأدوية
 
Donaciones apropiadas de medicamentos
Donaciones apropiadas de medicamentosDonaciones apropiadas de medicamentos
Donaciones apropiadas de medicamentos
 
Buenas practicas para la donación internacional de medicamentos
Buenas practicas para la donación internacional de medicamentosBuenas practicas para la donación internacional de medicamentos
Buenas practicas para la donación internacional de medicamentos
 
Bones pràctiques per a la donació internacional de medicaments
Bones pràctiques per a la donació internacional de medicaments Bones pràctiques per a la donació internacional de medicaments
Bones pràctiques per a la donació internacional de medicaments
 
Donacions Internacionals de Medicaments. Com fer-les apropiadament
Donacions Internacionals de Medicaments. Com fer-les apropiadamentDonacions Internacionals de Medicaments. Com fer-les apropiadament
Donacions Internacionals de Medicaments. Com fer-les apropiadament
 

Recently uploaded

systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 

Recently uploaded (20)

systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 

Good practice in international medicine donations

  • 1. Good practice in international medicine donations A project by: With the support of:
  • 2. 2 © Copyright by: Farmamundi Edited by: Farmamundi Catalunya C/Erasme de Janer 8 08001 - Barcelona Telf: 93 244 44 55 www.farmamundi.org With the support of: Design by: La Guspira Publication date: January 2019
  • 3. INDEX INTRODUCTION.......................................................................4 GENERAL CONSIDERATIONS...............................................5 SELECTION OF MEDICINES...................................................6 PRESENTATION, PACKAGING AND LABELLING............8 TRANSPORT..............................................................................9 INFORMATION AND MANAGEMENT............................11 MANAGEMENT OF USED MEDICINES............................13 KEY CONCEPTS.....................................................................13 ACRONYMS............................................................................15 BIBLIOGRAPHY.....................................................................15 NOTES.......................................................................................17
  • 4. 4 INTRODUCTION Medicine donations occur in very different circumstances; as a response to emergency situations, to humanitarian crises, or in long-term development aid projects. In emergency situations, part of the solidary response to the affected population is in the form of medicine donations. Although these contributions are almost always unquestionable and made in good faith, the rule “something is always better than nothing” is not correct. Even though; medicines are fundamental in humanitarian interventions they may have future negative consequences for the environment and for the health of the people of the receiving country. It has been found through the years, that medicines donated spontaneously do not always correspond to the needs of the emergency, the morbidity or the level of care of the recipient country. In these cases, not only candonationshavenegativeeffectsforthereceivingcommunitiesbutmayeven go unnoticed by health personnel or patients in the area, and not in line with the local pharmaceutical policies or the treatment guidelines of the country. It is also important to highlight the incorrect statement that “in situations of serious emergencies medicines with a short expiration date can be donated because they will be used quickly”, because it is precisely in these situations, when the systems for receiving, storing and distributing medicines, as it happens with other supplies, can be disrupted and overloaded, causing accumulations before its final distribution. These delays are especially serious when it comes to medicines, when their expiry date comes into play. Local and international health organizations, as well as public and private entities, have repeatedly denounced over the years, the massive arrival of medicines not usable in the countries affected by crisis situations, and the problems that derive from their incorrect storage, irrational use and eventual destruction. In 1996, the World Health Organization (WHO) [1] published for the first time a document of guidelines for medicine donations, reviewed and ratified in 1999 by this agency, as well as by social and international organizations, until the last update in 2010 [2]. These recommendations have served the international community as the basis for international legislation, such as the Guidelines on Good Distribution Practice of Medicinal Products for human use of the European Economic Community (EEC) [3] and national laws. In the case of the Spanish State, it is the Spanish Agency for Medicines and Health Products (AEMPS) [4] that regulates international medicine donations. These instructions for exports of medicines for humanitarian aid [5], are aimed at maintaining the quality standards of the medicines regardless of who the recipients are, and they forbid the donation of medicines that have already been used or that have left the pharmaceutical circuit.
  • 5. 5 GENERAL CONSIDERATIONS The aim of the WHO recommendations and of Spanish legislation on internationaldonationsofmedicines,istoensurethequalityofmedicinestoall people, whatever their circumstances. According to those recommendations and legislation, donated medicines must comply with all the international standards of quality, and not have abandoned the pharmaceutical circuit that ensures their traceability. International donations of medicines must always be endorsed by pharmaceutical staff who assume the responsibility for their quality and who certify their validity for shipment. It is also necessary that the recipient is informed, in good time, of the arrival date and the expiry dates of the medicines that, according to Spanish legislation, must be longer than 15 months. Only in very special circumstances and with the written acceptance of the recipient, medicines with lower expiry dates can be sent as a donation. This is so, because in many receiving countries, there may be logistical problems such as poor transport systems, storage problems or long distances between the ports of arrival and the final destination, delaying the delivery of the medicines. Similarly, the different storage levels from origin to destination (port or airport, central warehouse, provincial warehouse, district hospital, health centre) can lead to long delivery times of up to six to nine months, reducing the expiry dates of the medicines, before being delivered. Therefore, the recipients of the donation must be kept informed of the all stages of this process. They must also know the quantities and expiry dates of the medicines, because an excessive delay, in any of these phases, can imply quality deterioration of the medicines, affecting the stocks of the health centres, and generating harmful waste for the environment. The unusable medicines that arrive at destination should be eliminated in an appropriate manner, as they can become emerging organic pollutants, turning into an added problem for the recipient country, if it does not have adequate waste management processes. Whenever possible, donated medicines should be sent in big formats and appropriately labelled for final administration by the health professionals. Finally, it must be stressed that international donations of medicines cannot be managed by or sent to private individuals, but directly by non-
  • 6. 6 governmental organizations (NGOs) or humanitarian aid foundations, pharmaceutical laboratories, distributors of medicines, hospitals, health centres or governments, and addressed to governments or entities accredited by the Ministry of Health of the country of destination. SELECTION OF MEDICINES The medicines registered in Spain being selected for donation must always comply with all the international quality guarantees. In the case of medicines not registered in Spain, they must be: • registered in a European Union country (EU), or • registered outside the European Union and have the corresponding Certificate of Good Manufacturing Standards (GMP) issued by the European Union to guarantee their quality. In these cases, and exceptionally, the export can be authorized as a humanitarian donation and must be accompanied by a declaration signed by the recipient health authorities that details: a) identification of the medicines: name of the medicine, presentation and name of the manufacturing laboratory. b) express acceptance of the shipment, stating that they are aware that the donated medicine is not registered in the European Union. Donated medicines must have: • thesameguaranteesofquality,safetyandefficacyasthosebeingused in the country of origin and therefore remain within the pharmaceutical circuit, that is, in the legal chain of custody, until their final delivery. • a minimum expiry time of fifteen months upon arrival in the receiving country, with the exception of direct donations to certain health facilities. In these cases, a declaration from the recipient health personnel is necessary, acknowledging the expiry dates, storage conditions, and the amount being sent to prepare for the appropriate administration, before the expiry date.
  • 7. 7 • the prior authorization of the recipient, who has had to specify its needs. The legislation authorizes the recipient to refuse unsolicited donations, those that arrive without prior notice, or are not necessary, in order to guarantee the pharmaceutical policies and essential drug programmes of the recipient country, and maximize the positive impact of the donation, preventing the arrival of unnecessary and/or unknown medicines. • the presentation, dose and formulation as similar as possible to those of the recipient country to facilitate the work of its health personnel who are used to administering certain formulas and following dose guidelines without modification, so as not to affect the quality of their work. Neither medicines that come from patients’ returns, nor those provided as free samples to health personnel, can be donated, as it is not possible to guarantee their quality. Restrictions and exceptions * Psychotropic drugs, blood products, narcotics, heat-labile medicines or those with special storage and/or transportation conditions are given special consideration and their donation must be duly justified. These medicines
  • 8. 8 require a special export authorization, which is processed by the Narcotics and Psychotropic Area of the AEMPS, that will accompany the export authorization of medicines for humanitarian donations. * Vaccines, which apart from having special storage and/or transport conditions, are usually administered under national vaccination plans and international agreements, and consequently, not being part of smaller scale donations, between entities PRESENTATION, PACKAGING AND LABELLING To facilitate the administration, storage and distribution of international medicine donations, especially in emergency situations, clear identification of the boxes and their contents is very important, otherwise, the shipping operations can become very slow and laborious, delaying the delivery of medicines to the recipient. • The packaging must allow for clear identification of the medicines, thatis, includetheInternationalCommonDenomination(ICD)orgeneric name, dosage, pharmaceutical form, batch number, manufacturer and
  • 9. 9 expiry date. Receiving medicines with different or unknown names, can be a source of confusion for the heath personnel. In the case of injectables, the route of administration must also be clearly indicated. It is also recommended that the language of the labelling is intelligible for the health professionals of the receiving country. • It is advisable to adapt the packaging (commercial or hospital) to the conditions of the recipient, taking also into account issues like the price of different formats or means of transport, to maximizing the resources assigned to the donation. TRANSPORT At no time during the transport of the medicines, that is, from the warehouse of origin to their arrival in the receiving country, can the boxes that contain the medicines be opened, to add or remove any items. Until that moment, the number of boxes, weights and contents must correspond to the associated export documentation: commercial invoice, packing list and donation letter
  • 10. 10 stating that the donated goods will have, at destination, a non-commercial and assistance use. Medicines must be packed in separate boxes to the rest of the products, not mixing them with other types of supplies. To facilitate the handling of the shipment, without the need for special equipment, the boxes should not weigh more than 23kg. Costs Transportation costs (local and international), deposit and custody, customs clearance, storage or appropriate handling are borne by the donor entity, unless otherwise agreed in advance with the recipient, so as not to force it to allocate funds and efforts for the payment of customs and transport costs.
  • 11. 11 INFORMATION AND MANAGEMENT The export of medicines, as an international donation, together with the compulsory authorization of the AEMPS must accompany, for tax purposes, the necessary documentation: 1. commercial invoice based on the wholesale price of their generic equivalent in the local market. If this information is not available, one must consider the wholesale price in the world market of their generic equivalent. The declared value may also include management expenses. 2. packing list. 3. letter of donation issued by the donor entity indicating the destination, the value of the medicines, and a statement indicating that the donated medicines will be used for health purposes, and not commercial use. 4. information of the customs office of departure (port or airport). Because the documentation for the export includes the list of contents of each box, the authorization to the AEMPS must be requested, once the order is fully assembled. The application is free of charge and can be submitted: • In the virtual office of the AEMPS, going to the LABOFAR application: https://labofar.aemps.es/labofar/inicial.do • In paper format The export authorization of medicines: • is unique and exclusive for each donation, but not necessary for medical equipment and cosmetic products. • is valid for three months An authorized medicine donation may never have a commercial purpose.
  • 12. 12 There are two types of donour entities: A) with European Tax Identification Number: i. Shipments delivered in Spain; known informally as “suitcase shipments”. In these cases, the donor entity acts as an exporter of medicines and is ultimately responsible for the shipment. It is this entity that applies to the AEMPS for the export authorization of medicines and is responsible for the rest of the customs documentation. The responsibility of the medicines’ distributor ends with the delivery at the address given by the donor. Nonetheless, the distributor must provide the documentation and the advice, if necessary, for applying for the export authorization. ii. Shipments delivered to the country of destination. The distributor acts as the exporter and is responsible for the processing of the export authorisation and related documentation. B) ) with a non-European Tax Identification Number: Shipments are delivered in countries that are not members of the EU and are considered as commercial exports, thus not requiring a donation letter. In these cases, it is the distributor who is responsible for the export and custom procedures with the pertinent administrations. To apply for the export authorization of medicines, you must submit: 1) List of medication packaging indicating: • Name of the medicine (ICD). • Registrationnumber,whenthemedicineisregisteredformarketing in an EU Member State or a Certificate of Good Manufacturing Standards, in other circumstances. • Holder of the marketing authorization. • Presentation: pharmaceutical form, dosage and format and lot number. • Expiry date. • Number of boxes of each medicine. • Mention: These medicines are a free of charge donation of humanitarian character by (name of the entity). 2) Certificate signed by the responsible pharmacist who guarantees the shipment according to the criteria established for the international donation of medicines.
  • 13. 13 MANAGEMENT OF USED MEDICINES Left over medicines from our homes, as well as the empty packaging or with remnants of medicines, should be taken to the SIGRE Points [6] that are found in pharmacies, with their original boxes to facilitate their identification and their subsequent environmental treatment or other. Needles, thermometers, gauze and material for cures, chemicals, x-rays or batteries cannot be put into the SIGRE Points. As an exception, only when it is not possible to separate the needle, pre-filled syringes, insulin pens or other pens can they be taken to the SIGRE. In this case, they should always be deposited with the needle capped with their protective cap or similar. For safety and public health reasons, SIGRE Points are exclusively in pharmacies, so that the residues of medicines are always in the custody of pharmaceutical professionals. Finally, according to the Packaging and Packaging Waste Law (Law 1/1997 of April 24) [7] is the pharmaceutical productive sector who is obliged to assume the management of the waste of medicines that have to be destroyed in a controlled manner, and the recycling of the cardboard, glass, paper, etc., so as to not contaminate the environment. KEY CONCEPTS Bioequivalence Bioequivalence is the property wherein two drugs with identical active ingredients or two different dosage forms of the same drug possess similar bioavailability and produce the same effect at the site of physiological activity. Emerging contaminant Emerging contaminant is that previously unknown or not recognized substance, whose presence is not necessarily new, but what is new is the concern over its possible effects in the environment. The detection of these pollutants has only recently been possible thanks to the development of new and more sensitive analytical technologies.
  • 14. 14 Neglected diseases Neglected diseases are those that persist when there is poverty and are concentrated almost exclusively in the poor and impoverished countries of the world. These populations, living in remote rural areas, marginal suburban neighbourhoods or conflict zones, tend to be the most affected by these diseases,towhichlittleresearchanddevelopmentisdestinedandarerelegated from public health priorities because of their lack of political influence. Also, the lack of reliable statistics hinders initiatives to highlight them. Essential medicines Essential medicines are those that cover the priority health care needs of the population. Their selection is based on the prevalence of diseases and their safety,efficacyandcomparativecost-effectiveness.Nationaldruglistsindicate the essential medicines that must always be available, in sufficient quantities, in the appropriate pharmaceutical forms, with a guaranteed quality, and at a price that is affordable for people and for the community. TheWorldHealthOrganizationpublishedthefirstlistofessentialmedicinesin 1977, that is reviewed and updated every two years to adapt it to the changing health challenges in the world, serving as a model for Member States. In March 2017, the twentieth revision of the Essential Medicines List was published and the sixth revision for children under 12 years of age [8]. The twentieth list includes 433 medicines to treat priority diseases such as malaria, HIV/ AIDS, tuberculosis, reproductive health disorders and the increasingly chronic diseases, including cancer and diabetes.
  • 15. 15 Generic drugs Generic medicines are those that have the same qualitative and quantitative composition in active principles and the same pharmaceutical form as the original medicines and have demonstrated bioequivalence with the original medicines. Morbidity Morbidity is the number of people considered ill or victims of illness in a given space and time. Morbidity is an important statistical data to understand the evolution or regression of any disease, the reasons for its emergence and possible solutions.
  • 16. 16 ACRONYMS AEMPS AIDS EEC EU GMP HIV ICD NGO WHO - Agencia Española del Medicamento y Productos Sanitarios - Acquired Immunodeficiency Syndrome - European Economic Community – European Union – Good Manufacturing Practices - Human Immunodeficiency Virus - International Common Denomination - Non-Governmental Organization - World Health Organization
  • 17. 17 BIBLIOGRAPHY [1] Web page of the World Health Organisation (WHO). http://www.who.int/es/ [2] Guidelines for Medical Donations (WHO). http://apps.who.int/iris/bitstream/10665/44647/1/9789241501989_eng.pdf [3] ] Guidelines of 5 November 2013on Good Distribution Practice of medici- nal products for human use. https://www.aemps.gob.es/medicamentosUsoHumano/donaciones/docs/ins- trucciones-donacion-med.pdf [4] Web page of the Spanish Agency for Medicines and Health Products. (AEMPS). https://www.aemps.gob.es/ [5] Instructions for the export of medicnes for humanitarian donations. (AEMPS). Ministry of Health, Consumer Affairs and Social Welfare. https://www.aemps.gob.es/medicamentosUsoHumano/donaciones/docs/ins- trucciones-donacion-med.pdf [6] Web page of SIGRE (Sistema Integral de Gestión de Residuos y Envases). https://www.boe.es/buscar/doc.php?id=BOE-A-1997-8875 [7] Legislation on Packaging and Packaging Waste (Law 1/1997 April 24). BOE. http://www.sigre.es/ [8] WHO Model List of Essential Medicines. https://www.who.int/medicines/publications/essentialmedicines/20th_ EML2017.pdf?ua=1 WHO Model List of Essential Medicines for Children https://apps.who.int/iris/bitstream/handle/10665/273825/EMLc-6-eng. pdf?ua=1
  • 19. 19
  • 20. 20 A project by: With the support of: